Print  |  Close

Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)


Active: Yes
Cancer Type: Bile Duct Cancer
Breast Cancer
Colon/Rectal Cancer
Head and Neck Cancer
Lung Cancer
Melanoma
Neuroendocrine Tumor
Ovarian Cancer
Pancreatic Cancer
Sarcoma
NCT ID: NCT02568267
Trial Phases: Phase II Protocol IDs: RXDX-101-02 (primary)
NCI-2015-01848
Eligibility: 18 Years and older, Male and Female Study Type: Treatment
Study Sponsor: Hoffmann-La Roche
NCI Full Details: http://clinicaltrials.gov/show/NCT02568267

Summary

This is an open-label, multicenter, global Phase 2 basket study of entrectinib (RXDX-101) for
the treatment of patients with solid tumors that harbor an NTRK1/2/3, ROS1, or ALK gene
fusion. Patients will be assigned to different baskets according to tumor type and gene
fusion.

Treatment Sites in Georgia

University Cancer and Blood Center, LLC - Athens Medical Oncology
3320 Old Jefferson Road
Building 700
Athens, GA 30607
706-353-2990 x279
www.universitycancer.com



Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
404-778-5180
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.